Trial · NCT07877337
Microcurrent Therapy and the Post-Exercise Physiological Response (MENS_PE)
NCT07877337, Not applicable, Completed, University of Castilla-La Mancha
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Microcurrent Therapy and the Post-Exercise Physiological Response (MENS_PE). Trials, record NCT07877337. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877337
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Microcurrent Therapy and the Post-Exercise Physiological Response (MENS_PE)
- NCT number
- NCT07877337
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- University of Castilla-La Mancha
- Conditions
- Muscle Fatigue
- Interventions
- Microcurrents Therapy, Sham Microcurrent Therapy
- First posted
- 2026-10-16
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum creatine kinase (CK) concentration. | Baseline, 24 hours, and 48 hours after exercise. | Unit: U/L. Definition: Serum CK concentration will be measured at baseline and during the post- exercise recovery period at 24 and 48 hours. Baseline CK will be calculated as the mean of two measurements obtained one day before and on the day of the exercise protocol. The primary analysis will evaluate whether the CK concentrations over time differs between the active microcurrent and sham groups. |
| Secondary | Participant-perceived feasibility of microcurrent treatment administration | Immediately after the microcurrent treatment period. | Participants will report whether the intervention was easy to administer using a dichotomous response (Yes/No). The outcome will be summarized as the number and percentage of participants answering "Yes". |
| Secondary | Blood lactate concentration | Pre-exercise, immediately post-exercise, and 30 minutes post-exercise. | Unit: mmol/L. Definition: blood lactate concentration will be measured at baseline and inmediately post- exercise and at 30 min post-exercise. The analysis will focus on changes over time during the first 30 minutes of recovery. The primary comparisons will concern the effect of time rather than the effect of treatment group, because all lactate measurements are obtained before microcurrent treatment. These measurements will be considered indicators of biochemical response to the exercise bout rather than measures of the effect of microcurrent therapy. |
| Secondary | Change in perceived exertion after exercise | Immediately post-exercise and 30 minutes post-exercise. | Unit of Measure: Scale points from 0 to 10 Points Description: Rating of perceived exertion will be assessed using the Borg Category-Ratio 10 Scale immediately after the standardized exercise protocol and 30 minutes later. The recorded score ranges from a minimum of 0 ("nothing at all") to a maximum of 10 ("extremely strong-maximal exertion"). Higher scores indicate greater perceived exertion, representing a less favorable outcome in terms of perceived exertion. The change in perceived exertion will be calculated as the score at 30 minutes post-exercise minus the score immediately post-exercise. Possible change scores range from -10 to +10. Negative values indicate a reduction in perceived exertion, representing more favorable perceptual recovery; positive values indicate an increase, representing less favorable perceptual recovery. |
| Secondary | Participant and assessor blinding success | Immediately after completion of the study intervention. | Unit: Categorical responses Blinding success will be assessed by asking participants and outcome assessors to identify treatment allocation using five predefined response options: (1) strongly believe the treatment was active; (2) somewhat believe the treatment was active; (3) strongly believe the treatment was sham; (4) somewhat believe the treatment was sham; and (5) do not know |
| Secondary | Occurrence of adverse events | Immediately after the microcurrent treatment period. | The occurrence of adverse events will be recorded as a yes/no response for each participant. The outcome will be reported as the number of participants experiencing at least one adverse event. The nature and characteristics of reported adverse events will also be documented descriptively. |
| Secondary | Negative effects on sleep or rest | During and Immediately after the microcurrent treatment period. | Negative effects on sleep or rest during the microcurrent intervention will be assessed using participant-reported yes/no responses. The outcome will be reported as the number of participants reporting at least one negative effect on sleep or rest. The nature of reported effects will also be documented descriptively. |
| Secondary | Perceived unpleasantness of the microcurrent intervention | Immediately after the microcurrent treatment period. | Unit of Measure: Numerical Rating Scale (NRS) score (1-10). Description: Perceived unpleasantness of the microcurrent intervention will be assessed using a 11-point Numerical Rating Scale (NRS), ranging from 0 ("not unpleasant at all") to 10 ("extremely unpleasant"). Higher scores indicate greater perceived unpleasantness |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877337
GET https://conductscience.org/api/trials/v1/NCT07877337/registered